| __timestamp | CRISPR Therapeutics AG | Gilead Sciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1513000 | 2854000000 |
| Thursday, January 1, 2015 | 12573000 | 3014000000 |
| Friday, January 1, 2016 | 42238000 | 5098000000 |
| Sunday, January 1, 2017 | 69800000 | 3734000000 |
| Monday, January 1, 2018 | 113773000 | 5018000000 |
| Tuesday, January 1, 2019 | 179362000 | 9106000000 |
| Wednesday, January 1, 2020 | 266946000 | 5039000000 |
| Friday, January 1, 2021 | 438633000 | 5363000000 |
| Saturday, January 1, 2022 | 461645000 | 4977000000 |
| Sunday, January 1, 2023 | 387332000 | 6923000000 |
| Monday, January 1, 2024 | 320653000 | 5907000000 |
Data in motion
In the ever-evolving world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Gilead Sciences, Inc. and CRISPR Therapeutics AG have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Gilead Sciences consistently allocated a significant portion of its resources to R&D, with expenditures peaking at approximately $6.9 billion in 2023. This represents a more than 140% increase from its 2014 spending. In contrast, CRISPR Therapeutics, a pioneer in gene-editing technology, showed a remarkable growth trajectory, with R&D spending surging from a modest $1.5 million in 2014 to nearly $462 million in 2022, marking an exponential increase of over 30,000%. This stark difference highlights Gilead's established market presence and CRISPR's rapid ascent as a disruptive force in the biotech industry.
AbbVie Inc. or Gilead Sciences, Inc.: Who Invests More in Innovation?
R&D Insights: How Gilead Sciences, Inc. and Axsome Therapeutics, Inc. Allocate Funds
Comparing Innovation Spending: Gilead Sciences, Inc. and Catalyst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Gilead Sciences, Inc. and CRISPR Therapeutics AG
Research and Development Expenses Breakdown: Gilead Sciences, Inc. vs Perrigo Company plc
Comparing Innovation Spending: Gilead Sciences, Inc. and Novavax, Inc.
Research and Development Expenses Breakdown: United Therapeutics Corporation vs CRISPR Therapeutics AG
Analyzing R&D Budgets: Insmed Incorporated vs CRISPR Therapeutics AG
R&D Spending Showdown: BioMarin Pharmaceutical Inc. vs CRISPR Therapeutics AG
Who Prioritizes Innovation? R&D Spending Compared for CRISPR Therapeutics AG and Amphastar Pharmaceuticals, Inc.
CRISPR Therapeutics AG vs Galapagos NV: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: CRISPR Therapeutics AG vs BioCryst Pharmaceuticals, Inc.